A recent study showed that DMF (50–200 μM) is a promising agent that suppresses HCC growth by targeting the Nrf2-Bcl-xL signaling axis, a pathway associated with poor outcomes in certain HCC patients (Faleti et al., 2025). Here, NFE2L2 is linked to hepatocellular carcinoma.